Erythropoietin receptor expression and correlation to tamoxifen response and prognosis in breast cancer

Clinical Cancer Research

Volumn 15, Issue 17, 2009, Pages 5552-5559

  Larsson, Anna Maria ^a,b   Jirström, Karin ^a,b   Fredlund, Erik ^a,b   Nilsson, Sofie ^a   Rydén, Lisa ^a   Landberg, Göran ^a   Påhlman, Sven ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b Department of Endocrinology   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; ESTROGEN RECEPTOR; GOSERELIN; MESSENGER RNA; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER SURVIVAL; CELL CULTURE; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PREDICTOR VARIABLE; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; TISSUE MICROARRAY; TREATMENT RESPONSE;

BREAST NEOPLASMS; CELL LINE, TUMOR; ERYTHROPOIETIN; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; PROGNOSIS; RECEPTORS, ERYTHROPOIETIN; RNA, MESSENGER; TAMOXIFEN; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 69949089786     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-3014     Document Type: Article

References (43)

1. Moritz KM, Lim GB, Wintour EM. Developmental regulation of erythropoietin and erythropoiesis. Am J Physiol 1997;273:1829-1844
2. Semenza GL. Regulation of erythropoietin production. New insights into molecular mechanisms of oxygen homeostasis. Hematol Oncol Clin North Am 1994;8:863-884
3. Krantz SB. Erythropoietin. Blood 1991;77:419-434
4. Tilbrook PA, Klinken SP. The erythropoietin receptor. Int J Biochem Cell Biol 1999;10:1001-1005
5. Remy I, Wilson IA, Michnick SW. Erythropoietin receptor activation by a ligand-induced conformation change. Science 1999;283:990-993 (Pubitemid 129505219)
6. Sato T, Maekawa T, Watanabe S, Tsuji K, Nakahata T. Erythroid progenitors differentiate and mature in response to endogenous erythropoietin. J Clin Invest 2000;106:263-270 (Pubitemid 30483130)
7. Anagnostou A, Liu Z, Steiner M, et al. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci U S A 1994;91:3974-3978 (Pubitemid 24139555)
8. Masuda S, Okano M, Yamagishi K, Nagao M, Ueda M, Sasaki R. A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes. J Biol Chem 1994;269:19488-19493 (Pubitemid 24978761)
9. Yasuda Y, Masuda S, Chikuma M, Inoue K, Nagao M, Sasaki R. Estrogen-dependent production of erythropoietin in uterus and its implication in uterine angiogenesis. J Biol Chem 1998;273:25381-25387 (Pubitemid 28443305)
10. Sawyer ST, Krantz SB, Sawada K. Receptors for erythropoietin in mouse and human erythroid cells and placenta. Blood 1989;74:103-109 (Pubitemid 19187416)
11. Ogilvie M, Yu X, Nicolas-Metral VJ, et al. Erythropoietin stimulates proliferation and interferes with differentiation of myoblasts. Biol Chem 2000;275:39754-39761 (Pubitemid 32059005)
12. Westenfelder C, Biddle DL, Baranowski RL. Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int 1999;55:808-820 (Pubitemid 29100693)
13. Juul SE, Joyce AE, Zhao Y, Ledbetter DJ. Why is erythropoietin present in human milk? Studies of erythropoietin receptors on enterocytes of human and rat neonates. Pediatr Res 1999;46:263-268 (Pubitemid 29400568)
14. Acs G, Acs P, Beckwith SM, et al. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 2001;61:3561-3565 (Pubitemid 32694960)
15. Yasuda Y, Fujita Y, Masuda S, et al. Erythropoietin is involved in growth and angiogenesis in malignant tumours of female reproductive organs. Carcinogenesis 2002;23:1797-1805 (Pubitemid 35355929)
16. Yasuda Y, Fujita Y, Matsuo T, et al. Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 2003;24:1021-1029 (Pubitemid 36833185)
17. Batra S, Perelman N, Luck LR, Shimada H, Malik P. Pediatric tumor cells express erythropoietin and a functional erythropoietin receptor that promotes angiogenesis and tumor cell survival. Lab Invest 2003;83:1477-1487 (Pubitemid 37267831)
18. Arcasoy MO, Amin K, Karayal AF, et al. Functional significance of erythropoietin receptor expression in breast cancer. Lab Invest 2002;82:911-918 (Pubitemid 34761666)
19. Hardee ME, Arcasoy MO, Blackwell KL, Kirkpatrick JP, Dewhirst MW. Erythropoietin biology in cancer. Clin Cancer Res 2006;12:332-339
20. Elliott S, Busse L, Bass MB, et al. Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood 2006;107:1892-1895 (Pubitemid 43289368)
21. Della Ragione F, Cucciolla V, Borriello A, Oliva A, Perrotta S. Erythropoietin receptors on cancer cells: a still open question. J Clin Oncol 2007;25:1812-1813 (Pubitemid 46797967)
22. Larsson AM, Landberg G, Påhlman S, Albertsson M. Erythropoietin enhances response to treatment in patients with advanced breast cancer. Acta Oncol 2004;43:594-687
23. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin α in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005;23:5960-5972 (Pubitemid 46300213)
24. Henke M, Laszig R, Rübe C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-1260 (Pubitemid 37324251)
25. Rydén L, Jönsson PE, Chebil G, et al. Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up. Eur J Cancer 2005;41:256-264 (Pubitemid 40136540)
26. Jirström K, Rydén L, Anagnostaki L, et al. Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trial. J Clin Pathol 2005;58:1135-1142 (Pubitemid 41566455)
27. Rydén L, Jirström K, Bendahl PO, et al. Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer. J Clin Oncol 2005;23:4695-4704 (Pubitemid 46224072)
28. Kronblad A, Jirstrom K, Rydén L, Nordenskjöld B, Landberg G. Hypoxia inducible factor-1α is a prognostic marker in premenopausal patients with intermediate to highly differentiated breast cancer but not a predictive marker for tamoxifen response. Int J Cancer 2006;118:2609-2616
29. Svensson S, Jirström K, Rydén L, et al. ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis. Oncogene 2005;24:4370-4379 (Pubitemid 40961760)
30. Gobert S, Duprez V, Lacombe C, Gisselbrecht S, Mayeux P. The signal transduction pathway of erythropoietin involves three forms of mitogen-activated protein (MAP) kinase in UT7 erythroleukemia cells. Eur J Biochem 1995;234:75-83.
31. Holmquist-Mengelbier L, Fredlund E, Löfstedt T, et al. Recruitment of HIF-1α and HIF-2α to common target genes is differentially regulated in neuroblastoma: HIF-2α promotes an aggressive phenotype. Cancer Cell 2006;10:413-423 (Pubitemid 44693470)
32. Löfstedt T, Jögi A, Sigvardsson M, et al. Induction of ID2 expression by hypoxia-inducible factor-1: a role in dedifferentiation of hypoxic neuroblastoma cells. J Biol Chem 2004;279:39223-39231 (Pubitemid 39258183)
33. Vandesompele J, De Preter K, Pattyn F, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002;3:7.
34. Holmquist L, Jögi A, Påhlman S. Phenotypic persistence after reoxygenation of hypoxic neuroblastoma cells. Int J Cancer 2005;116:218-225 (Pubitemid 40967258)
35. Verdier F, Gomez S, Lacombe C, Mayeux P. Selected anti-Epo receptor antibodies predict Epo receptor expression. Blood 2006;108:1106. (Pubitemid 44154652)
36. Helczynska K, Kronblad A, Jögi A, et al. Hypoxia promotes a dedifferentiated phenotype in ductal breast carcinoma in situ. Cancer Res 2003;63:1441-1444 (Pubitemid 36373625)
37. Miller LD, Smeds J, George J, et al. An expression signature for p53s tatus in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A 2005;102:13550-13555 (Pubitemid 41420886)
38. Kokhaei P, Abdalla AO, Hansson L, et al. Expression of erythropoietin receptor and in vitro functional effects of epoetins in B-cell malignancies. Clin Cancer Res 2007;13:3536-3544 (Pubitemid 46955113)
39. Henke M, Mattern D, Pepe M, et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol 2006;24:4708-4713
40. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869-10874
41. Ali S, Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2002;2:101-112 (Pubitemid 37328797)
42. Massarweh S, Schiff R. Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities. Clin Cancer Res 2007;13:1950-1954 (Pubitemid 46649859)
43. Stendahl M, Kronblad A, Rydén L, Emdin S, Bengtsson NO, Landberg G. Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients. Br J Cancer 2004;90:1942-1948 (Pubitemid 38746334)